LB-100

Phase 2Small molecule

LLixte Biotechnology Holdings, Inc.

LB-100 is one of 150 small molecule programs targeting Colorectal Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

149

Competitors

Pipeline

Status by Indication[3][1]

Indication

Colorectal CarcinomaRecruiting

Metastatic Colorectal CancerActive, not recruiting

GlioblastomaActive, not recruiting

Myelodysplastic SyndromesActive, not recruiting

Ovarian Clear Cell CarcinomaRecruiting

Colorectal CarcinomaPhase 1

Recruiting

Metastatic Colorectal CancerPhase 1

Active, not recruiting

GlioblastomaPhase 2

Active, not recruiting

Myelodysplastic SyndromesPhase 1/Phase 2

Active, not recruiting

Ovarian Clear Cell CarcinomaPreclinical

Recruiting

Competition

Competitive Landscape

698 competitors in Metastatic Colorectal Cancer

#DrugCompanyPhaseTrials

Vectibix

Amgen

Phase 3

45 2

Lynparza

AstraZeneca

Phase 3

2 3

Zocor

OOrganon and Co

Phase 3

4 4

Alinia

RRomark Laboratories L.C.

Phase 3

1 5

Cosela

PPharmacosmos A/S

Phase 3

1 6

XL092

Roche

Phase 3

1 7

HX008

BBinhui Biopharmaceutical Co., Ltd.

Phase 3

1 8

Mfolfoxiri

DDominik Paul Modest

Phase 3

2 9

LB-100

LLixte Biotechnology Holdings, Inc.

Phase 2

4 10

Eylea

Regeneron

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

PreclinicalRecruiting

Ovarian Clear Cell Carcinoma

NCT06065462

Q3 2028

Phase 1Recruiting

Colorectal Carcinoma

NCT06012734

Clinical

Trials by Indication[1]

Glioblastoma1 trial

Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT03027388·7 enrolled

Myelodysplastic Syndromes1 trial

A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

Recruiting·LLixte Biotechnology Holdings, Inc.·Phase 1/2·NCT03886662·47 enrolled

Colorectal Carcinoma1 trial

Phase Ib Study With the Combination of LB-100 (PP2A Inhibitor) and Atezolizumab (PD-L1 Inhibitor) in Metastatic Colorectal Cancer Patients - The CoLBAt Trial

Recruiting·TThe Netherlands Cancer Institute·Phase 1·NCT06012734·37 enrolled

Ovarian Clear Cell Carcinoma1 trial

Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100

Recruiting·MM.D. Anderson Cancer Center·Preclinical·NCT06065462·21 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for LB-100. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LB-100 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LB-100. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Lixte Biotechnology Holdings, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: LLixte Biotechnology Holdings, Inc.

LB-100

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q3 2028

Trials by Indication[1]

Glioblastoma1 trial

Myelodysplastic Syndromes1 trial

Colorectal Carcinoma1 trial

Ovarian Clear Cell Carcinoma1 trial

References

Drug Info

Quick Facts

Related News